Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO)

Angiology

Volumn 51, Issue 2, 2000, Pages 131-139

  Jeren Strujic B ^a   Raos, V ^a   Jeren, T ^a   Horvatin Godler, S ^a  

^a University of Zagreb School of Medicine   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMATOCRIT; HEMODIALYSIS; HEMODYNAMICS; HUMAN; MALE; MICROCIRCULATION; PHYSICAL CAPACITY; QUALITY OF LIFE;

EID: 0033970192     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970005100206     Document Type: Article

References (39)

1. Cotes PM, Pippard MJ, Reid CD, et al: Characterization of the anemia of chronic renal failure and mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 70:113-137, 1989.
2. Eschbach JW, Egrie JC, Dowining MR, et al: Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987.
3. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-148, 1989.
4. Desforges JF: Anemia in uremia. Arch Intern Med 126:808-811, 1970.
5. Besarab A, Kristen K, Flaharty AJ, et al: Clinical pharmacology and economics of recombinant human erythropoietin in end stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 2:1405-1415, 1992.
6. McGonigle RJS, Wallin JD, Shadduck RK, et al: Erythropoietin deficiency and inhibition of erythropolesis in renal insufficiency. Kidney Int 35:437-444, 1984.
7. Peter W: Erythropoietin. Transfus Sci 12:15-23, 1991.
8. Katona M, Turi S, Bodrogi T: Regression of left ventricular hypertrophy and erythropoietin treatment. In: Erythropoiesis: New Dimensions in the Treatment of Anemia, v. III. London: Adis International Limited, 1992, pp 39-45.
9. Silberberg JS, Barre PE, Prichard SS, et al: Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int 36:286-290, 1989.
10. Silberberg JS, Rahal DP, Patton R, et al: Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64:222-224, 1989.
11. Gosse PH, Roudaut R, Dallocchio M: Is echocardiography an adequate method to evaluate left ventricular hypertrophy regression? Eur Heart J 11 (suppl G):107-112, 1990.
12. Shan DJ, De Maria A, Kisslo J, et al: Recommendations regarding quantitation in M mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58:1072-1083, 1977.
13. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 55:613-618, 1977.
14. Teichholz LE, Kreulen T, Herman MV, et al: Problems in echocardiographic volume determinations: Echocardiographic angiographic correlations in the presence or absence of asynergy. Am J Cardiol 37:7-11, 1976.
15. Radermacher J, Koch KM: Treatment of renal anemia by erythropoietin substitution. The effects on cardiovascular system. Clin Nephrol 44 (suppl 1):856-860, 1995.
16. Wizemann V, Schafer R, Kramer W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left ventricular hypertrophy. Nephron 64:202-206, 1993.
17. Kannel WB, Gorton T, Offutr D: Left ventricular hypertrophy in ECG prevalence incidence and mortality in the Framingham study. Ann Intern Med 71:89-105, 1969.
18. Pascual J, Teruel JL, Moya L, et al: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 35:280-287, 1991.
19. Levy D, Robert MD, Garison MS, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322:1561-1566, 1990.
20. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95-110, 1992.
21. Harnett JD, Kent GM, Foley RN, et al: Cardiac function and hematocrit level. Am J Kidney Dis 25:(suppl 4):3-7, 1995.
22. Harnett JD, Parfrey PS, Griffiths SM, et al: Left ventricular hypertrophy in end stage renal disease. Nephron 48:107-115, 1988.
23. Martinez-Vea AV, Bardaji A, Garcia C, et al: Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 4:353-357, 1992.
24. Low I, Grutzmacher P, Bergmann M, et al: Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 31:26-30, 1989.
25. Low-Friedrich I, Grutzmacher P, Marz W, et al: Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 11:54-60, 1991.
26. Cannella G, La Canna G, Sandrini M, et al: Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clinc Nephrol 34:272-278, 1990.
27. Walls J: Hemoglobin is more better? Nephrol Dial Transplant 10 (suppl 2):56-61, 1995.
28. Cozma G: r-HuEPO and the cardiovascular system in CRF. Bio-News Scientific 38:1-5, 1994.
29. London GM, Zins B, Pannier B, et al: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:878-882, 1989.
30. Goldberg N, Lundin P, Delano B, et al: Changes in left ventricular size, wall thickness and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 124:424-427, 1992.
31. Haedersdal C, Mehlsen J, Stenver D, et al: Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure. Angiology 45:231-234, 1994.
32. Hon G, Vaziri ND, Kaupke CJ, et al: Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. Artif Organs 19:188-191, 1995.
33. Nissenson AR: Erythropoietin overview. Blood Purif 12:6-13, 1994.
34. Macdougall JC, Lewis NP, Saunders MJ, et al: Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 335:489-493, 1990.
35. Nowicki M: Erythropoietin and hypertension. J Hum Hypertens 9:81-88, 1995.
36. Liang DY, Chang YM, Ding YA: Effects of erythropoietin on blood pressure in patients undergoing regular hemodialysis. Acta Cardiol Sin 3:139-144, 1995.
37. Sand BI, Buttimore AL, Hurrell MA: Hemorrheology and fistula function in home hemodialysis patients following erythropoietin treatment: A prospective placebo controlled study. Nephron 64:53-57, 1993.
38. Minagawa T, Hirano T, Takada N, et al: The effect of recombinant human erythropoietin on left ventricular mass and left ventricular hemodynamics in hemodialysis patients. Nippon Jinzo Gakkai Shi 36:934-941, 1994.
39. Mann JF: Hypertension and cardiovascular effects long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 2 (suppl 10):80-84, 1995.